» Articles » PMID: 11586105

Pilot Evaluation of 1p and 19q Deletions in Anaplastic Oligodendrogliomas Collected by a National Cooperative Cancer Treatment Group

Overview
Journal Am J Clin Oncol
Specialty Oncology
Date 2001 Oct 5
PMID 11586105
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Radiation Therapy Oncology Group (RTOG) trial 94-02 is designed to compare the effectiveness of radiation therapy alone with radiation therapy plus procarbazine, lomustine, and vincristine (PCV) chemotherapy in patients with anaplastic oligodendrogliomas and mixed oligoastrocytomas. This prospectively collected, randomly treated, prospectively followed cohort is the ideal set of patients to validate the observation that anaplastic oligodendrogliomas with 1p and 19q deletions have a prolonged survival and a better response to chemotherapy. For patients entered on RTOG 94-02, fresh blood specimens, as well as slides and paraffin blocks, have been obtained (with informed consent) on enrollment. Peripheral blood leukocytes (buffy coats) have been frozen and stored and Epstein-Barr-virus-immortalized lymphoblastoid lines have been prepared from the blood specimens. In this report, the authors describe a pilot 1p/19q deletion analysis of 26 tumors from RTOG trial 94-02. In this analysis, it is shown that 1p/19q deletion analysis by fluorescence in situ hybridization is feasible on blocks collected from this trial. Also demonstrated is that the incidence of 1p and 19q deletions in this pilot series of anaplastic oligodendrogliomas and mixed oligoastrocytomas is similar to that reported in previous studies. When the clinical follow-up on this prospective trial is mature and the deletion studies have been completed, the authors should be able to determine whether 1p and 19q deletions predict a prolonged survival and/or responsiveness to PCV chemotherapy plus radiation in patients with anaplastic oligodendrogliomas and mixed oligoastrocytomas.

Citing Articles

Intratumoral calcification: not only a diagnostic but also a prognostic indicator in oligodendrogliomas.

Zhu Q, Jiang H, Cui Y, Ren X, Li M, Zhang X Eur Radiol. 2023; 34(6):3674-3685.

PMID: 37968476 DOI: 10.1007/s00330-023-10405-9.


Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).

Ahn G, Hwang K, Kim T, Park C, Chang J, Jung T Cancer Res Treat. 2021; 54(2):396-405.

PMID: 34237210 PMC: 9016307. DOI: 10.4143/crt.2021.393.


Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).

Hwang K, Kim T, Park C, Chang J, Jung T, Kim J Cancer Res Treat. 2019; 52(2):505-515.

PMID: 31671938 PMC: 7176949. DOI: 10.4143/crt.2019.421.


Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent M, Baumert B, Erridge S, Vogelbaum M, Nowak A, Sanson M Lancet. 2017; 390(10103):1645-1653.

PMID: 28801186 PMC: 5806535. DOI: 10.1016/S0140-6736(17)31442-3.


CNS Anticancer Drug Discovery and Development Conference White Paper.

Levin V, Tonge P, Gallo J, Birtwistle M, Dar A, Iavarone A Neuro Oncol. 2015; 17 Suppl 6:vi1-26.

PMID: 26403167 PMC: 4581696. DOI: 10.1093/neuonc/nov169.